{"name":"Grünenthal GmbH","slug":"gr-nenthal-gmbh","ticker":"","exchange":"","domain":"grunenthal.com","description":"","hq":"Aachen","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"neuroscience","drugs":[{"name":"Placebo Plaster","genericName":"Placebo Plaster","slug":"placebo-plaster","indication":"Other","status":"phase_3"},{"name":"Lopain","genericName":"Lopain","slug":"lopain","indication":"Other","status":"phase_1"},{"name":"Matching Placebo (twice daily)","genericName":"Matching Placebo (twice daily)","slug":"matching-placebo-twice-daily","indication":"Other","status":"phase_3"},{"name":"Progesterone vaginal ring","genericName":"Progesterone vaginal ring","slug":"progesterone-vaginal-ring","indication":"Other","status":"phase_3"},{"name":"Tapentadol Prolonged Release with Pregabalin","genericName":"Tapentadol Prolonged Release with Pregabalin","slug":"tapentadol-prolonged-release-with-pregabalin","indication":"Other","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"infectious","drugs":[{"name":"Tapentadol Prolonged Release","genericName":"Tapentadol Prolonged Release","slug":"tapentadol-prolonged-release","indication":"Moderate to severe chronic pain in adults requiring opioid therapy","status":"marketed"},{"name":"CG5503 IR","genericName":"CG5503 IR","slug":"cg5503-ir","indication":"Chronic pain conditions (Phase 3 development)","status":"phase_3"},{"name":"Oxycodone/Naloxone Prolonged Release","genericName":"Oxycodone/Naloxone Prolonged Release","slug":"oxycodone-naloxone-prolonged-release","indication":"Chronic moderate to severe pain requiring prolonged opioid therapy","status":"marketed"},{"name":"Tramadol 50","genericName":"Tramadol 50","slug":"tramadol-50","indication":"Moderate acute and chronic pain","status":"phase_3"},{"name":"Tramadol/Diclofenac 50/50","genericName":"Tramadol/Diclofenac 50/50","slug":"tramadol-diclofenac-50-50","indication":"Moderate to severe pain","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"respiratory","drugs":[{"name":"Clarithromycin DST (125 mg)","genericName":"Clarithromycin DST (125 mg)","slug":"clarithromycin-dst-125-mg","indication":"Bacterial respiratory tract infections","status":"phase_3"},{"name":"Clarithromycin DST (187.5 mg)","genericName":"Clarithromycin DST (187.5 mg)","slug":"clarithromycin-dst-187-5-mg","indication":"Bacterial respiratory tract infections","status":"phase_3"},{"name":"Clarithromycin DST (250 mg)","genericName":"Clarithromycin DST (250 mg)","slug":"clarithromycin-dst-250-mg","indication":"Bacterial respiratory tract infections","status":"phase_3"},{"name":"Clarithromycin Syrup (125 mg)","genericName":"Clarithromycin Syrup (125 mg)","slug":"clarithromycin-syrup-125-mg","indication":"Bacterial respiratory tract infections (community-acquired pneumonia, acute bronchitis)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Diclofenac 50","genericName":"Diclofenac 50","slug":"diclofenac-50","indication":"Acute pain (postoperative, dental, musculoskeletal)","status":"phase_3"},{"name":"Topical analgesic","genericName":"Topical analgesic","slug":"topical-analgesic","indication":"Localized musculoskeletal pain","status":"marketed"},{"name":"Tramadol/Diclofenac 25/25","genericName":"Tramadol/Diclofenac 25/25","slug":"tramadol-diclofenac-25-25","indication":"Moderate to severe pain","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"GRT9906","genericName":"GRT9906","slug":"grt9906","indication":"Chronic cough","status":"phase_2"},{"name":"RTX-GRT7039","genericName":"RTX-GRT7039","slug":"rtx-grt7039","indication":"Chronic cough","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Morphine Sulphate Controlled Release","genericName":"Morphine Sulphate Controlled Release","slug":"morphine-sulphate-controlled-release","indication":"Moderate to severe chronic pain","status":"phase_3"}]}],"pipeline":[{"name":"Morphine Sulphate Controlled Release","genericName":"Morphine Sulphate Controlled Release","slug":"morphine-sulphate-controlled-release","phase":"phase_3","mechanism":"Morphine sulphate is an opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and pain relief.","indications":["Moderate to severe chronic pain","Cancer pain"],"catalyst":""},{"name":"Diclofenac 50","genericName":"Diclofenac 50","slug":"diclofenac-50","phase":"phase_3","mechanism":"Diclofenac inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.","indications":["Acute pain (postoperative, dental, musculoskeletal)","Chronic inflammatory conditions (rheumatoid arthritis, osteoarthritis)","Dysmenorrhea"],"catalyst":""},{"name":"GRT9906","genericName":"GRT9906","slug":"grt9906","phase":"phase_2","mechanism":"GRT9906 is a selective antagonist of the P2X3 receptor that reduces pain signal transmission in sensory neurons.","indications":["Chronic cough","Neuropathic pain"],"catalyst":""},{"name":"Placebo Plaster","genericName":"Placebo Plaster","slug":"placebo-plaster","phase":"phase_3","mechanism":"Placebo Plaster is an inert transdermal patch formulation designed to serve as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Tapentadol Prolonged Release","genericName":"Tapentadol Prolonged Release","slug":"tapentadol-prolonged-release","phase":"marketed","mechanism":"Tapentadol is a mu-opioid receptor agonist and noradrenaline reuptake inhibitor that provides analgesia through dual mechanisms.","indications":["Moderate to severe chronic pain in adults requiring opioid therapy"],"catalyst":""},{"name":"Topical analgesic","genericName":"Topical analgesic","slug":"topical-analgesic","phase":"marketed","mechanism":"Topical analgesics work by delivering pain-relieving agents directly to the skin and underlying tissues to reduce localized pain sensation.","indications":["Localized musculoskeletal pain","Minor arthritis pain","Muscle aches and strains"],"catalyst":""},{"name":"CG5503 IR","genericName":"CG5503 IR","slug":"cg5503-ir","phase":"phase_3","mechanism":"CG5503 is a selective inhibitor of transient receptor potential vanilloid 1 (TRPV1) that reduces pain signaling by blocking capsaicin-sensitive nociceptors.","indications":["Chronic pain conditions (Phase 3 development)"],"catalyst":""},{"name":"Clarithromycin DST (125 mg)","genericName":"Clarithromycin DST (125 mg)","slug":"clarithromycin-dst-125-mg","phase":"phase_3","mechanism":"Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.","indications":["Bacterial respiratory tract infections","Helicobacter pylori eradication (as part of combination therapy)","Atypical pneumonia (Mycoplasma, Chlamydia)"],"catalyst":""},{"name":"Clarithromycin DST (187.5 mg)","genericName":"Clarithromycin DST (187.5 mg)","slug":"clarithromycin-dst-187-5-mg","phase":"phase_3","mechanism":"Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.","indications":["Bacterial respiratory tract infections","Helicobacter pylori eradication (as part of combination therapy)","Mycobacterial infections (MAC prophylaxis/treatment)"],"catalyst":""},{"name":"Clarithromycin DST (250 mg)","genericName":"Clarithromycin DST (250 mg)","slug":"clarithromycin-dst-250-mg","phase":"phase_3","mechanism":"Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.","indications":["Bacterial respiratory tract infections","Helicobacter pylori eradication (as part of combination therapy)","Atypical mycobacterial infections"],"catalyst":""},{"name":"Clarithromycin Syrup (125 mg)","genericName":"Clarithromycin Syrup (125 mg)","slug":"clarithromycin-syrup-125-mg","phase":"phase_3","mechanism":"Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth.","indications":["Bacterial respiratory tract infections (community-acquired pneumonia, acute bronchitis)","Otitis media","Sinusitis","Skin and soft tissue infections","Helicobacter pylori eradication (as part of combination therapy)"],"catalyst":""},{"name":"Lopain","genericName":"Lopain","slug":"lopain","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Matching Placebo (twice daily)","genericName":"Matching Placebo (twice daily)","slug":"matching-placebo-twice-daily","phase":"phase_3","mechanism":"Matching placebo has no active pharmacological mechanism; it is an inert control formulation used in clinical trials.","indications":[],"catalyst":""},{"name":"Oxycodone/Naloxone Prolonged Release","genericName":"Oxycodone/Naloxone Prolonged Release","slug":"oxycodone-naloxone-prolonged-release","phase":"marketed","mechanism":"Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is included to reduce the potential for abuse by blocking opioid effects if the tablet is crushed and injected.","indications":["Chronic moderate to severe pain requiring prolonged opioid therapy"],"catalyst":""},{"name":"Progesterone vaginal ring","genericName":"Progesterone vaginal ring","slug":"progesterone-vaginal-ring","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RTX-GRT7039","genericName":"RTX-GRT7039","slug":"rtx-grt7039","phase":"phase_3","mechanism":"RTX-GRT7039 is a selective antagonist of the P2X3 receptor that reduces pain signaling by blocking ATP-mediated nociceptive transmission.","indications":["Chronic cough","Neuropathic pain"],"catalyst":""},{"name":"Tapentadol Prolonged Release with Pregabalin","genericName":"Tapentadol Prolonged Release with Pregabalin","slug":"tapentadol-prolonged-release-with-pregabalin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tramadol 50","genericName":"Tramadol 50","slug":"tramadol-50","phase":"phase_3","mechanism":"Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief.","indications":["Moderate acute and chronic pain"],"catalyst":""},{"name":"Tramadol/Diclofenac 25/25","genericName":"Tramadol/Diclofenac 25/25","slug":"tramadol-diclofenac-25-25","phase":"phase_3","mechanism":"Tramadol is a centrally acting opioid analgesic, while diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis.","indications":["Moderate to severe pain","Osteoarthritis"],"catalyst":""},{"name":"Tramadol/Diclofenac 50/50","genericName":"Tramadol/Diclofenac 50/50","slug":"tramadol-diclofenac-50-50","phase":"phase_3","mechanism":"Tramadol is a centrally acting opioid analgesic, while diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis.","indications":["Moderate to severe pain","Inflammatory pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOY3JURmZ2anpnWWNkcFFyVmFxVHpHRWY0S1hqdjBXdDhpVnNoTWtOc1M3cnR0azI0OF9nUXFCTnBXZFFPY3RkTzI3WEVsVi1VcnNPSnFrWFRxM2ZqZkRjRl9ZZnNTYWk5d1FUSGFTeDFfcUNHMENlaWpDQVU0TGxSaA?oc=5","date":"2024-12-02","type":"pipeline","source":"lw.com","summary":"Latham & Watkins Advises Grünenthal on €500 Million Bond - lw.com","headline":"Latham & Watkins Advises Grünenthal on €500 Million Bond","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWThmZUNlWGhIMF8zbXFJTmk5ZHFuWUxxbmJrQjljRmlLS0hTN21RanlOUnN5MFFBbXF2VU5IY3h4eFR2Z2cyLTdkSFR3QkRrUTNEb283aFJDV1hoUFV3VkM0WWhmUGdqQ2pNVWI0cTlMZDhYazFTRExKUWoxNVJxeTFhQjFrYU1uTXpWQ3ZlZVZSSUxxX3hudGF2OUx5UnhWY1FDazdHbUJ4Rms?oc=5","date":"2024-07-22","type":"pipeline","source":"Fierce Pharma","summary":"Grünenthal continues US growth push with $250M acquisition of Valinor Pharma - Fierce Pharma","headline":"Grünenthal continues US growth push with $250M acquisition of Valinor Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPN3RnQW9tU29pWExSZWFKcmZSaFNTRHotdE90Z3N1N0M3UFlXOVFYVVNMSkxnMTJIT0RtMWRpQkhxWDR5ZGtIZkxyRDVDbEkzVV9SLXpKLW03alI2RWVDMl9UbXAydVRVbVRyeEpHekp5cm5WSDFPNlcwbmVMUHlrMmUzaFhHa1FjQU5aaDE2VFk5NGNqQVB4VWEwTUZpX3NaSE1OQUdyanVJc2pvNEhxeEhYWnZwQy1OLWtPNg?oc=5","date":"2024-04-25","type":"trial","source":"Mintz","summary":"Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out - Mintz","headline":"Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPWjlPcXAxSUxaWWpGdmVvTWN4bngxeVdaZFdSYi01UzhmWUNDNklJeV9Pc3d3WDFEbXpLcVFLS3JPV0JNZmUxM0cyem9FbUNQblByc3FNRW1kS2dlZUw2bHgxSk9EMTBuVlFrUHV3RHlUSEtQcGcteGtTOG01bFF1SnNkUllNYTI5WFBiUXBmeXEtQU1lUEVnRkxudEg?oc=5","date":"2023-08-02","type":"deal","source":"Contract Pharma","summary":"Grünenthal, Kyowa Kirin International Enter Joint Venture Collaboration - Contract Pharma","headline":"Grünenthal, Kyowa Kirin International Enter Joint Venture Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE40cGVZN3VaRUhYVWx4VFQ4VXBCa0ZPb1ZRdnlIWXFZYTBxWVdSYm84alFMX1ZYeDBpc0xBUjJzTy1oUHg0VEFKdnpkZ0hYNlNjaGdGS0dBNDBnNUdoSjNmTTZR?oc=5","date":"2023-04-15","type":"pipeline","source":"TradingView","summary":"XS233770353 Bond Price and Chart — MUN:XS233770353 - TradingView","headline":"XS233770353 Bond Price and Chart — MUN:XS233770353","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOdDllVWh4MnROWlpKNWpjbEVJcFJyMjRIVG9UR1lENkJKZ1VxTkFBUDlfODh6VEw2VDNPSmpTQnVCQ1ZsUU1JcGJXd25DcDFQTFp6Q3hUZ28wYjNTaExZX0ZTWUw1T250QlpWOXM5em9SeDJfTXNlbWIycUlEUERaOFphOFJHYWlRdmZOU3dxUXFyWENMOGZ3SEowYW5fVm1kZm1Ob1BQZU9sbVJtMktWcQ?oc=5","date":"2023-03-14","type":"patent","source":"Akin","summary":"Federal Circuit Affirms Invalidation of Purdue Pharma’s OxyContin Patents - Akin","headline":"Federal Circuit Affirms Invalidation of Purdue Pharma’s OxyContin Patents","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWUMzVnpwbGRvSWZ1TnlDcjZ4T18zVGVUM2xYU3lETzQ5X01mRXJUb2FSUEk1UWotRTRvSnBIc2tYV1FiU2xscEpaZnVxQ2dNQXpReTczRjBKbkRMbHRqLXhLMDFLNER0bHNJTTJwaXlPOUlzd3VHelRoWVJkaDl4V1lGRVZWR1BhS1NlZGU0SmJCaXp4aGVCVndpNGk5cmVYcFVUaUQ2RzFqZEYtYmVIb3pNVlhUVk41MnJsYlJTQlVWT3M?oc=5","date":"2021-04-12","type":"pipeline","source":"Fierce Pharma","summary":"Grünenthal's transformation: CEO Gabriel Baertschi about what's ahead for the global leader in pain management - Fierce Pharma","headline":"Grünenthal's transformation: CEO Gabriel Baertschi about what's ahead for the global leader in pain management","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNdGZuVFYtUWRJUUhXTXdrVG43WVpKYVhkVktBbnB0ODFFSDR5OHBfaGhNWXJJWktxU0xtcHJUd3VsRmgyN0hsbWtVdGk2ZFZBcG41SWhCSlFhUjJoM3NYWUYwQU9WUVA0RlFsajJYMXNZTGc2MDVXUnZEYlRQcDEwM0t2U043LW9acjY3TG9lQWM0QWRmMUhGbk1RLTBkUVZwX096c0x2djlXelRRUnpJU0dn?oc=5","date":"2020-11-30","type":"pipeline","source":"Reuters","summary":"AstraZeneca sells former blockbuster cholesterol drug for $320 mln - Reuters","headline":"AstraZeneca sells former blockbuster cholesterol drug for $320 mln","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB4Vm9BX19TdTl4UGRYbTFwNGphRG5sMmdKaUR4bl83SzNsWTJCejU0UFJGNUE3UnNOUWtsTDRZZTdJV2lYcEwxcFRLUFdoYmR4UzNZSGpTYnBNeG1Lc0sw?oc=5","date":"2020-09-01","type":"deal","source":"Nature","summary":"Grünenthal: driving innovative treatments in pain and beyond through collaboration and partnerships - Nature","headline":"Grünenthal: driving innovative treatments in pain and beyond through collaboration and partnerships","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE0zMFZCWExsWGZLc3Ftb1hGcEljZVpHbnRlX2hSQlBLUXh5aU1GejdmREZ1dzJXOGtSbHZRa1QtbjBmc2NGYWsxQkdXYjVxS1MtNGo1ZjAzYkJUa3hOS1ZTSWZSZkJEc0J4MXdoUjlxNmp4Rk0?oc=5","date":"2019-05-30","type":"pipeline","source":"pharmaphorum","summary":"Mundipharma, Grünenthal accused of kickbacks in Italy - pharmaphorum","headline":"Mundipharma, Grünenthal accused of kickbacks in Italy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQYy13QlZHWHdvTC1nbV9WUUJvVG9yS3c5cGpZNjRzdWg1dkVvakVnNHo0YjNYc0ExaG9rTFBrVXdWLXRaQjkzcFZRY2hlck1veVJKTDdWM2QtRXg5SnhZZVFLSGU1eHlobzdRazVoQjR1ZTUzTVpUOHAxZ21TLWU3U3JMMGM?oc=5","date":"2019-04-05","type":"pipeline","source":"JD Supra","summary":"Federal Circuit Addresses Obviousness of Polymorphs in Grunenthal GmbH v. Alkem Labs. Ltd., No. 2017-1153 (Fed. Cir. Mar. 28, 2019) - JD Supra","headline":"Federal Circuit Addresses Obviousness of Polymorphs in Grunenthal GmbH v. Alkem Labs. Ltd., No. 2017-1153 (Fed. Cir. Mar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQcVV0RHVrdHM0dUg4T3BpeTNuQVVfRV9aelRfeERDWWJkMjR5elNiZkhmUTd2YkF5dzFpNmRJNkhGWDFfXzQ5SUJ5NVFXR05CbFM1dVYzeDRYQ0pQV29aanI3M1RVM2JOZlRUQlJGYkIyTVhQSm5MQm5GczBkdS1CWEhGVmhLSGtra3NtVHB2bmYwRHp0LTFMU1MwT0JBaFZNUTZXVWVMM1YwaUdSWWh0TFdodTM5SmlxTTRzVWdRZG93UVZQallFT2MtSHkxdHNfMEs0WUhheU51cFE1VW9wTVhGSFJaZw?oc=5","date":"2016-06-02","type":"deal","source":"AstraZeneca","summary":"AstraZeneca licenses Zurampic to Grünenthal GmbH in Europe and Latin America - AstraZeneca","headline":"AstraZeneca licenses Zurampic to Grünenthal GmbH in Europe and Latin America","sentiment":"neutral"}],"patents":[],"drugCount":20,"phaseCounts":{"phase_3":14,"phase_2":1,"marketed":4,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}